JP Morgan, BTIG and Jefferies initiated analyst coverage on molecular diagnostics firm BillionToOne, assigning a range of ratings and price targets that reflect optimism about the company’s noninvasive prenatal testing (NIPT) and oncology prospects. JP Morgan opened with an Overweight and $150 target, BTIG with a Buy at $160 and Jefferies with a Hold at $117; the report noted BillionToOne’s IPO in November and a market reaction that left shares down in morning trading. Analysts highlighted demand for the company’s single‑gene NIPT (sgNIPT) product, Quantitative Counting Templates (QCT) single‑molecule detection technology, and an expanding oncology portfolio including Northstar Select and a pan‑cancer MRD test targeted for 2026. Coverage emphasized potential share gains in a commoditizing aneuploidy NIPT market and differentiated technology for MRD and therapeutic monitoring. The initiation reflects increasing Wall Street focus on sequencing‑based diagnostics and the commercial scaling of advanced NIPT and liquid‑biopsy offerings.